Rare blood disorders pose a unique set of diagnostic and therapeutic challenges. Their subtle presentation can often mimic more prevalent conditions, leading to delayed diagnoses and treatment. However, recent breakthroughs in precision medicine are transforming the management of these conditions, with a focus on pioneering research in disorders like haemophilia, sickle cell disease, and transthyretin amyloidosis.
Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.
Our supporting partners do not constitute an endorsement of the content on this page.
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.
Three experts discuss the burden of myelofibrosis and anaemia/thrombocytopenia and targeted treatment options.
Protagonist Therapeutics Inc. and Takeda have shared positive topline findings from the phase III VERIFY trial (NCT05210790), which investigated rusfertide in patients with polycythemia vera (PV) who require frequent phlebotomies. Participants were randomly assigned to receive either rusfertide or a ...
Three expert haematologists discuss current and emerging treatments for ITP as well as the disease burden.
Three experts discuss data presented at EHA and ISTH 2024 on the impact and management of ITP.
Two haematologic oncologists discuss optimizing the use of JAK inhibitors for patients with myelofibrosis.
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.
Or use a Social Account.
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.